Morimoto K, Yamada T, Furuya N, Tanaka H, et al. Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study. Lung Cancer 2025;201:108447.
PMID: 39970730